Please login to the form below
Hybrigenics appoints Dr Alain Munoz
France-based bio-pharmaceutical company Hybrigenics has appointed Dr Alain Munoz to its board of directors
France-based bio-pharmaceutical company Hybrigenics has appointed Dr Alain Munoz to its board of directors.
Dr Munoz replaces Dr Bernhard Ehmer, president of ImClone Systems, and will chair the clinical advisory board.
He has over 20 years' experience in the pharmaceutical industry at senior management level with the Sanofi Group as R&D vice-president and the French pharmaceutical company Fournier as VP of R&D and business development, subsequently becoming senior VP of the pharmaceutical division.
As well as his position at Hybrigenics, Dr Munoz is also a board member of several biotechnology companies including Novagali Pharma and Zealand Pharma.
Share
Related Hub content
Featured jobs
-
Account Director, Medical Education
-
Salary TBC
- Senior / Principal Medical Writer – Medical Education - UK &...
-
Excellent Salary and Benefits on offer
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
-
Senior Medical Writer
-
Salary TBC
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Scientific Director - Medical Communications Agency - New York
-
Excellent Remuneration Package
- Scientific Director - Medical Education - Cheshire & London ...
-
Excellent Remuneration Package
- Senior Medical Writer – Leading Medical Communications Agency – ...
-
Highly Competitive Remuneration Package
- Experienced / Senior Medical Writer - MedComms - Cardiff - Wales
-
Excellent Salary and Benefits on offer
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Graduate / Entry Level Opportunities – Medical Communications – ...
-
Highly Competitive Remuneration Package
Subscribe to our email news alerts
- Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn
- Regeneron reveals first data for bispecific antibody in multiple myeloma
- Merck buys ArQule for $2.7bn in another cancer bolt-on deal
- J&J splashes $750m on anti-inflammatory drug bermekimab
- Healthcare trends 2020 – the biggest shifts changing lives and life sciences
- AstraZeneca’s Calquence impresses in previously untreated CLL
PMHub
JPA Health Communications
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- The 2019 CPhI Pharma Index Report
- Examining this year’s industry performance...
- Five key trends in precision and personalised healthcare
- Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
- OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
- Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Quick links
Infographics
